



PTO/SB/08B (08-03)

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/308,080		
		Filing Date	October 28, 1999		
		First Named Inventor	Gonzales, Ph.D., Frank		
		Art Unit	1652		
		Examiner Name	Ramirez, Delia M.		
Sheet	2	of	2	Attorney Docket Number	015280-271100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR	2	KUILENBURG, Andre B.P. et al.: "Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD Deficiency"; <u>Clinical Cancer Research</u> , Vol. 7; pp. 1149-1153; May 2001	
DR	3	KUIVANIEMI, Helena et al.: "Identical G+1 to A mutations in three different introns of the Type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers- Danlos Syndrome IV"; <u>J. Biological Chemistry</u> , Vol. 265, No. 20; pp. 12067-12074; July 15, 1990	
DR	4	YOKOTA, Hiroshi et al.: "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, and enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria"; <u>J. Biological Chemistry</u> , Vol. 269, No. 37; pp. 23192-23196; September 16, 1994	
DR	5	OMIM Entry for "Dihydropyrimidine Dehydrogenase; DPYD" printed on December 3, 2003; http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=274270 ; 10 pages	

Examiner Signature		Date Considered	3/18/04
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Compl to If Known

Application Number	09/308,080
Filing Date	October 28, 1999
First Named Inventor	Frank Gonzalez
Group Art Unit	1652
Examiner Name	Steadman, D
Attorney Docket Number	015280-271100US

RECEIVED
APR 18 2002
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR	AC	Gonzalez, F., et al., "Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency," <i>TIPS</i> , 16:325-327 (1995).	
	AD	YOKOTA, Hiroshi, et al., "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria," <i>J. Biol. Chem.</i> , 269:23192-23198 (1994).	
	AE	JOURNAL BIOLOGICAL CHEMISTRY, vol. 264, no. 20, July 1990, pages 12087-74, XP002032886 KUIVANIEMI, H., ET AL: "Identical G to a mutations in three different introns of the type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers-Danlos Syndrome IV," see abstract	
	AF	Meisema, R., et al., "Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Results in Exon Skipping and Thymine Uraciluria," <i>DNA & Cell Biol.</i> , 14(1):1-6 (1995).	
	AG	NUCLEIC ACIDS RESEARCH, vol. 15 no. 14, 1987, pages 5813-28, XP002032885 MARVIT, J. ET AL: "GT to AT transition at a splice donor site causes skipping of the preceeding exon in phenylketonuria" see abstract	
	AH	SINGAPORE JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 28, no. 3, November 1995, pages 176-86, XP000800337 ROY ET AL: "molecular scanning of human diseases" see the whole document.	
	AI	Vreken, P., et al., "A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency," <i>J. Inher. Metab. Dis.</i> , 19(5):645-54 (1996).	
DR	AJ	Wei, X., et al., "Molecular Basis of the Human Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluorouracil Toxicity," <i>J. Clin. Invest.</i> , 98(3):610-615 (1996).	

Examiner Signature	<i>DS</i>	Date Considered	6/30/02
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9039543 v1